Characterization of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostate cancer cell lines

Prostate Cancer and Prostatic Diseases

Volumn 6, Issue 1, 2003, Pages 15-26

  Daja, M M ^a   Niu, X ^a   Zhao, Z ^a   Brown, J M ^a   Russell, P J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Human prostate cancer cell lines; LNCaP derived cell lines; Matrix metalloproteinases (MMPs); Membrane type MMPs (MT MMPs); PC 3 derived cell lines; Tissue inhibitors of metalloproteinases (TIMPs)

Indexed keywords

COLLAGENASE 3; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MEMBRANE TYPE 2 MATRIX METALLOPROTEINASE; MEMBRANE TYPE 3 MATRIX METALLOPROTEINASE; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

CANCER CELL CULTURE; CANCER INVASION; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEQUENCE ANALYSIS; STROMA CELL; WESTERN BLOTTING; ZYMOGRAPHY;

BLOTTING, WESTERN; DNA PRIMERS; HUMANS; MALE; MATRIX METALLOPROTEINASES; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0037248004     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500609     Document Type: Review

References (80)

1. Kantoff PW, Wishnow KI, Loughlin KR. Prostate Cancer: a Multi-disciplinary Guide. Blackwell Science: Massachusetts, 1997, 296 pp.
2. Yoneda T. Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone. Eur J Cancer 1998; 34: 240-245.
3. Lichte A, Kolkenbrock H, Tschesche H. The recombinant catalytic domain of membrane-type matrix metalloproteinase-1 (MT1-MMP) induces activation of progelatinase A and progelatinase A complex with TIMP-2. FEBS Lett 1996; 397: 277-282.
4. Matrisian LM. Melloproteinases and their inhibitors in matrix remodelling. Trends Gen 1990; 6: 121-125.
5. Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Resp J 1994; 7: 2062-2072.
6. Birkedal-Hansen H. Proteolytic remodelling of extracellular matrix. Curr Opin Cell Biol 1995; 7: 728-735.
7. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999; 189: 300-308.
8. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-21494.
9. Seiki M. Membrane-type matrix metalloproteinases. APMIS 1999; 107: 137-143.
10. Ellerbroek SM, Stack MS. Membrane associated matrix metalloproteinases in metastasis. BioEssays 1999; 21: 940-949.
11. Sato H et al. Matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370: 61-65.
12. Takino T, Sata H, Shinagawa A, Seiki M. Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. J Biol Chem 1995; 270: 23013-23020.
13. Puente XS et al. Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res 1996; 56: 944-949.
14. Will H, Hinzmann B. cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane domain. Eur J Biochem 1995; 231: 602-608.
15. Pei D. Identification and characterisation of the fifth membrane-type matrix metallo-proteinase MT5-MMP. J Biol Chem 1999; 274: 8925-8932.
16. Atkinson S et al. Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes. J Biol Chem 1995; 270: 30479-30485.
17. Strongin AY et al. Mechanism of cell surface activation of 73kDa type IV collagenase. J Biol Chem 1995; 270: 5331-5338.
18. Knauper V et al. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme. J Biol Chem 1996; 271: 17124-17131.
19. Stanton H et al. The activation of proMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45kDa form. J Cell Sci 1998; 111: 2789-2798.
20. Lohi J et al. Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbol 12-myristate 13-acetate. Eur J Biochem 1996; 239: 239-247.
21. Ohuchi E et al. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macro-molecules. J Biol Chem 1997; 272: 2446-2451.
22. Henriet P, Blavier L, Declerck YA. Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation. APMIS 1999; 107: 111-119.
23. Brown PD, Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol 1995; 6: 967-974.
24. Jung L et al. Matrix metallo-proteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metallo-proteinase-1/tissue inhibitor in plasma of patients with prostate cancer. Int J Cancer 1997; 74: 220-223.
25. Baker T et al. Serum metallo-proteinases and their inhibitors: markers for malignant potential. Br J Cancer 1994; 70: 506-512.
26. Still K et al. Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue. Prostate 2000; 42: 18-25.
27. Wood M et al. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 1997; 15: 246-258.
28. Gohji K et al. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer 1998; 79: 96-101.
29. Boag H. Transforming growth factor-beta-1 and matrix metalloproteinases in prostatic adenocarcinoma and hyperplasia-coordinated patterns of immunohistochemical expression. Appl Immunohistochem 1997; 5: 246-251.
30. Montironi R et al. Immunohistochemical evaluation of type IV collagenase (72-kD metalloproteinase) in prostatic intraepithelial neoplasia. Anticancer Res 1996; 16: 2057-2062.
31. Stearns M, Stearns ME. Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. Oncol Res 1996; 8: 69-75.
32. Stearns M, Stearns ME. Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a) expression in human prostate cancer. Oncol Res 1996; 8: 63-67.
33. Hashimoto K, Kihara Y, Matuo Y, Usui T. Expression of matrix metallo-proteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate. J Urol 1998; 160: 1872-1876.
34. Hamdy FC et al. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 1994; 69: 177-182.
35. Upadhyay J et al. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Clin Cancer Res 1999; 5: 4105-4110.
36. Pyke C, Ralfkilaelr E, Tryggvason K, Dano K. Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol 1993; 142: 359-365.
37. Bassett P et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990; 348: 699-704.
38. Okada A et al. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast and head and neck carcinomas. Proc Natl Acad Sci USA 1995; 92: 2730-2734.
39. Horoszewicz JS et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43: 1809-1818.
40. Navone NM, Logothetis CJ, von Eschenbach AC, Troncoso P. Model systems of prostate cancer: Uses and limitations. Cancer Metast Rev 1999; 17: 361-371.
41. Gleave M et al. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991; 51: 3753-3761.
42. Wu HC et al. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994; 57: 406-412.
43. Wu TT et al. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer 1998; 77: 887-894.
44. Thalmann GN et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994; 10: 2577-2581.
45. Kaighn ME et al. Establishment and characterisation of a human prostatic carcinoma cell lien (PC3). Invest Urol 1979; 17: 16-23.
46. Pettaway CA et al. Selection of highly metastatic variants of different human prostate carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 1996; 2: 1627-1636.
47. Stephenson RA et al. Metastatic model for human prostate cancer using orthoptopic implantation in nude mice. J Natl Cancer Inst 1992; 84: 951-957.
48. Repesh LA. A new in vitro assay for quantitating tumour cell invasion. Invasion and Metastasis 1989; 9: 192-208.
49. Giambernadi TA et al. Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol 1998; 16: 483-496.
50. Ishiguro N et al. mRNA expression of matrix metalloproteinases and tissue inhibitors of metallo-proteinase in interface tissue around implants in loosening total hip arthroplasty. J Biomed Mater Res 1996; 32: 611-617.
51. Lyons JG et al. Characteristics of a 95-kDa matrix metalloproteinase produced by mammary carcinoma cells. Biochemistry 1991; 30: 1449-1456.
52. Hurwitz A, Dushnik M, Solomon H, Yagel S. Cytokine-mediated regulation of rat ovarian function: interleukin-1 stimulates the accumulatioin of a 92-kilodalton gelatinase. Endrocrinology 1993; 132: 2709-2714.
53. Perkinson RA, Kuo BA, Norton PA. Modulation of transcription of the rat fibronectin gene by cell density. J Cell Biochem 1996; 63: 74-85.
54. Ballock RT et al. TGF-β1 prevents hypertrophy of epiphyseal chondrocytes: regulation of gene expression for cartilage matrix proteins and metalloproteinases. Devel Biol 1998; 158: 414-429.
55. Wagner S et al. Expression of matrix metalloproteinases in human glioma cell lines in the presence of Il-10. J. Neurol Oncol 1998; 40: 113-122.
56. Sanchez-Sweatman OH, Orr FW, Singh G. Human metastatic prostate PC3 cell lines degrade bone using matrix metalloproteinases. Invasion Metastasis 1999; 18: 297-305.
57. Goltzman D. Mechanisms of the development of osteoblastic metastases. Cancer 1997; 80: 1581-1587.
58. Cooper CR, Pienta KJ. Cell adhesion and chemotaxis in prostate cancer metastasis to bone: a minireview. Prostate Cancer Prostat Dis 2000; 3: 6-12.
59. Stetler-Stevenson WG, Hewitt R, Corcoran M. Matrix metalloproteiinases and tumour invasion: from correlation and causality to the clinic. Sem Cancer Biol 1996; 7: 147-154.
60. MacDougall JR, Matrisian LM. Contributions of tumour and stromal matrix metallo-proteinases to tumour progression, invastion and metastasis. Cancer Metastas Rev 1995; 14: 351-362.
61. Segain J-P et al. Induction of fibroblast gelatinase B expression by direct contact with cell lines derived from primary tumour but not from metastases. Cancer Res 1996; 56: 5506-5512.
62. Martorana AM et al. Epithelial cells up-regulate matrix metalloproteinases in cells within the same mammary carcinoma that have undergone an epithelial-mesenchymal transition. Cancer Res 1998; 58: 4970-4979.
63. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinase family members in breast cancer represents a tumour-induced host response. Am J Pathol 1996; 149: 273-282.
64. Benbow U et al. A novel host/tumour cell interaction activates matrix metallo-proteinase 1 and mediates invasion through type I collagen. J Biol Chem 1999; 274: 25371-25378.
65. McGuire PG, Seeds NW. The interaction of plasminogen activator with a reconstituted basement membrane matrix and extracellular macromolecules produced by cultured epithelial cells. J Cell Biochem 1989; 40: 215-227.
66. Dong Z et al. Differential regulation of matrix metalloproteinase-9, tissue inhibition of metalloproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of prostate cancer and stromal cells. Int J Cancer 2001; 93: 507-515.
67. Ware JL, Paulson DF, Mickey GH, Webb KS. Spontaneous metastasis of cells of the human prostate carcinoma cell line PC-3 in athymic nude mice. J Urol 1982; 128: 1064-1067.
68. Gonzales-Gronow M et al. Interaction of plasminogen with dipeptidyl peptidase IV initiates a signal transduction mechanism which regulates expression of matrix metalloproteinase-9 by prostate cancer cells. Biochem J 2001; 355: 397-407.
69. Pendas AM et al. An overview of collagenase-3 expression in malignant tumors and analysis of its potential value as a target in antitumor therapies. Clin Chim Acta 2000; 291: 137-155.
70. Uria JA et al. Regulation of collagenase-3 expression in human breat carcinomas is mediated by stromal-epithelial cell interactions. Cancer Res 1997; 57: 4882-4888.
71. Nagakawa O et al. Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines. Cancer Lett 2000; 155: 173-179.
72. Desruisseau S, Ghazarossian-Ragni E, Chinot O, Martin P-M. Divergent effect of TGFβ1 on growth and proteolytic modulation of human prostatic-cancer cell lines. Int J Cancer 1996; 66: 796-801.
73. Achbarou A et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 1994; 54: 2372-2377.
74. Sehgal I, Baley PA, Thompson TC. Transformsing growth factor beta 1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res 1996; 56: 3359-3365.
75. Festuccia C et al. Osteoblast-derived TGF-β1 modulates matrix degrading protease expression and activity in prostate cancer cells. Int J Cancer 2000; 85: 407-415.
76. Sehgal I, Thompson TC. Novel regulation of type IV collagenase (matrix metallo-proteinase-9 and -2) activities by transforming growth factor-β1 in human prostate cancer cell lines. Mol Biol Cell 1999; 10: 407-416.
77. Yonou H et al. Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. Cancer Res 2001; 61: 2177-2182.
78. Attisano L, Lee-Hoeflich ST. The smads. Genone Biol 2001; 2: Reviews 3010.1-3010.8
79. Yuan W, Varga J. Transforming growth factor-β repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. J Biol Chem 2001; 276: 38502-38510.
80. Webber MM, Waghray A, Bello D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1995; 1: 1089-1094.